Paclitaxel

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

Retrieved on: 
Wednesday, December 6, 2023
Woman, Associate, Trastuzumab, FACP, Radiation, Therapy, National Cancer Institute, Emory University, Conference call, Breast cancer, NCI, Cleveland Clinic, Medicine, McGill University, FRCPC, MBBS, Conference, Harvard Medical School, Cancer, Outline of health sciences, Immunotherapy, Minda, Warren Alpert Foundation Prize, Communications satellite, Pharmaceutical industry, MD, Paclitaxel

SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.

Key Points: 
  • All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.
  • Anixa is pleased to invite all interested parties to participate in a conference call today at 6:30 p.m.
  • Jennifer Davis: Ms. Davis is a nurse, wife, mother of three, and Triple Negative Breast Cancer survivor.
  • Dr. Shepard is best known as the inventor of the life-saving breast cancer drug Herceptin® (trastuzumab).

Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer

Retrieved on: 
Thursday, November 16, 2023
Orbis, Carboplatin, Paclitaxel, Priority review, Woman, Oncology nursing, Health Canada, Annual general meeting, SGO, Policy, Food, Platinum, Gynecologic Oncology (journal), US Foods, ESMO, Patient, Society of Gynecologic Oncology, Part, FDA, GOC, Endometrial cancer, Health, Standard of care, Cancer, CCSN, Survival, Partnership, Oncology, Society, MSI-H, Birth control, Pharmaceutical industry, Dostarlimab, MISSISSAUGA

Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.

Key Points: 
  • Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.
  • [1]
    "Today's approval supports our ambition for Jemperli to advance the standard of care for Canadian adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer," said Marni Freeman, Country Medical Director at GSK Canada.
  • "This expanded approval of Jemperli offers a new care option to healthcare professionals treating this patient population with high unmet need."
  • "The CCSN is pleased to see a newly approved innovative treatment option for patients in Canada.

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Bispecific monoclonal antibody, Patient, FDA, PD-L1, Trial of the century, IND, Therapy, Paclitaxel, G&A, AUC, PD-1, Doctor of Philosophy, Entrepreneurship, Stage 2, Development, CRC, Key Stage 1, Research and development, DLL4, Safety, Management, Fine chemical, Nursing, Pharmaceutical industry, Cryptocurrency, Research, Compass, MD, BTC

Transition to take place on January 9th 2024

Key Points: 
  • Transition to take place on January 9th 2024
    Ended the third quarter with $164 million in cash and marketable securities, providing cash runway for the company into 2026
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results.
  • During the first nine months of 2023, the Company used $28 million of cash to fund operations.
  • R&D expenses were $8.8 million for the quarter ended September 30, 2023, as compared to $9.8 million for the same period in 2022, a decrease of approximately $1.0 million or 10%.
  • G&A expenses were $3.1 million for the quarter ended September 30, 2023, as compared to $2.8 million for the same period in 2022, an increase of $0.3 million or 10%.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Research, PRS, Carboplatin, Ovarian cancer, Trae Waynes, Traveller Alien Module 2: K'kree, Oncology nursing, Partnership, CBR, September 5, ATR, CCNE1, Circulating tumor DNA, OR, BMS, Paclitaxel, Ono, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Glomus tumor, Roche, Net, Safety, Therapy, Cancer, Patient, DNA, MRR, Conference, Clinical trial, Anemia, IST, AACR, Red Barricades: ASL Historical Module 1, FOLFIRI, Genotype, PPP2R1A, PKMYT1, FBXW7, Princess Margaret Cancer Centre, RECIST, Modularity, PARP, Pharmaceutical industry, Vaccine, Reinsurance, Reparenting, G&A, IND

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, NSCLC, Food, Pancreas, Anastrozole, Regulatory affairs, Ovarian cancer, GAAP, Pancreatic Cancer Action Network, Paclitaxel, Accelerated approval (FDA), ORR, European Network of Transmission System Operators for Electricity, Safety, Cancer, Therapy, Investment, Patient, General Administration of Sport of China, Verastem Oncology, Topotecan, Conference, Bank statement, Clinical trial, FRAME, Travel, Letrozole, RAMP, FDA, SOC, AACR, RAS, Research and development, The Annual Global Orgasm for Peace, GOG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KRAS, Senior, Pharmacokinetics, European Society of Gynaecological Oncology, Lung cancer, Table, Diagnosis, Pharmaceutical industry, Bank, Finance

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the third quarter of 2023 with cash, cash equivalents and investments of $165.7 million.
  • Research & development expenses for the 2023 Quarter were $13.9 million, compared to $11.3 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.4 million for the 2022 Quarter.

New Research in JNCCN Suggests a Simple and Inexpensive Option for Reducing a Major Chemotherapy Side-Effect

Retrieved on: 
Tuesday, November 7, 2023
Patient, National Comprehensive Cancer Network, Huntsman Cancer Institute, Incidence, Chemotherapy-induced peripheral neuropathy, Biomarker, Vitamin D deficiency, MD, Doctor of Philosophy, Research, Finger, Hypoesthesia, Quality of life, Paclitaxel, The, Risk, CIPN, Doctor of Pharmacy, Sensation, University, Paresthesia, University of Michigan, University of Michigan Rogel Cancer Center, Cancer, Cleveland Clinic, Breast cancer, Neuropathic pain, University of Michigan College of Pharmacy, Peripheral neuropathy, Vitamin D, Dietary supplement, Pharmacy

PLYMOUTH MEETING, Pa., Nov. 7, 2023 /PRNewswire/ -- New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy. According to an analysis of 1,191 patients with early-stage breast cancer—using data collected in the SWOG S0221 study—20.7% of patients with vitamin D deficiency experienced at least a grade 3 level of chemotherapy-induced peripheral neuropathy (CIPN), compared to 14.2% of those with sufficient vitamin D levels. The researchers also found that inducing vitamin D deficiency in an accompanying mice model study caused neurotoxicity-like symptoms.

Key Points: 
  • The researchers also found that inducing vitamin D deficiency in an accompanying mice model study caused neurotoxicity-like symptoms.
  • "There are barely any negative consequences that come from taking steps to increase vitamin D levels.
  • The researchers also noted that it is well-established that vitamin D deficiency is more common in self-reported Black patients.
  • This research holds the promise of shedding future light on the mechanisms underlying CIPN and the potential identification of biomarkers that could predict CIPN incidence."

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening

Retrieved on: 
Tuesday, November 7, 2023
Data Management, Biotechnology, Alternative Medicine, Technology, FDA, Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Carboplatin, AACR, HCI, WES, Organoid, 2D, RNA, Cisplatin, Crown Bioscience International, Timeline, Doctor of Philosophy, KRAS, Senior, Sequence, Paclitaxel, RNA-Seq, NGS, Drug discovery, PDX, ANE, CTG, AR, Automation, Medical imaging, Vitro

This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.

Key Points: 
  • This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.
  • Screening of a large panel of patient-derived organoids is enabled using Crown Bioscience’s unique assay-ready (AR) organoid technology.
  • OrganoidXplore transcends traditional 2D cell culture systems in terms of patient relevance, heralding a significant leap in preclinical drug screening.
  • The Full Panel currently comprises 50 organoid models covering seven cancer indications, which are also available as companion Patient-Derived Xenografts (PDX).

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Retrieved on: 
Monday, November 6, 2023
ASX, MHC, IDMC, Data monitoring committee, Optimus, Paclitaxel, Autoimmune disease, Safety, IMM, Cancer, Patient, Toxicity, Pharmaceutical industry

SYDNEY, AUSTRALIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the open-label safety lead-in of its integrated AIPAC-003 Phase II/III trial evaluating for the very first time 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues.

Key Points: 
  • The IDMC recommended proceeding to the randomised Phase II portion of the trial.
  • The randomised (1:1) Phase II portion of the study will now open to include up to 58 evaluable patients with metastatic breast cancer receiving either 30mg efti or 90mg efti to determine the optimal biological dose.
  • Importantly the determination of the optimal biological dose is relevant for the whole efti program across all disease indications.
  • The integrated Phase II/III AIPAC-003 trial is evaluating efti, Immutep’s soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with standard-of-care paclitaxel for the treatment of metastatic hormone receptor positive (HR+), HER2-negative or HER2-low breast cancer and triple-negative breast cancer.

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Retrieved on: 
Friday, November 3, 2023
ASX, MHC, PD-L1, NSCLC, Gamma ray, Poster, ESMO, Progression-free survival, Biomarker, TPS, RNA, Society for Immunotherapy of Cancer, Pembrolizumab, GEP, AIPAC, Merck, CD8, SITC, T cell, Immunotherapy, Paclitaxel, Immune system, Annual general meeting, ALC, Blood, Autoimmune disease, Serum, Gene, Lung cancer, CXCL10, Lymphocyte, IMM, Cancer, Society, Monocyte, Patient, Merck & Co., Vaccine, Medical imaging, Pharmaceutical industry, LAG-3

SYDNEY, AUSTRALIA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial evaluating eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC Class II agonist administered subcutaneously, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment for patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Dr Frederic Triebel, Immutep CSO, said, “Immunomonitoring of blood cells is of prime importance when one would like to understand the effect of a systemic immunostimulant injected subcutaneously, like efti is.
  • Importantly, the pharmacodynamic data from efti in combination with pembrolizumab is associated with the 35.5-month median Overall Survival in first-line treatment of metastastic non-small cell lung cancer patients expressing PD-L1 (TPS >1%) that we recently reported at ESMO 2023.
  • This biomarker data from the TACTI-002 Phase II is similar to the biomarker analysis from Immutep’s randomized, double-blind AIPAC Phase IIb trial in HER2-/HR+ metastatic breast cancer, which combined efti solely with paclitaxel chemotherapy and did not include any anti-PD-1 therapy.
  • The poster titled “Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab” will be available on the Posters & Publications section of Immutep’s website.

Occlusion Perfusion Catheter Demonstrates Superior Performance in PAD Drug Delivery

Retrieved on: 
Thursday, November 2, 2023
ACT, Frontiers in Cardiovascular Medicine, Peripheral artery disease, De novo, Sirolimus, Paclitaxel, Cardiology, Pressure, Disease, Complete circumferential peripheral and deep margin assessment, Restenosis, OPC, Safety, BTK, Stent, PAD, Medical device, Pharmaceutical industry

CHATTANOOGA, Tenn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Occlusion Perfusion Catheter (OPC), a multi-lumen balloon catheter from Advanced Catheter Therapies (ACT), was recently selected by researchers for use in exploring a new treatment approach for peripheral artery disease (PAD) and restenosis.

Key Points: 
  • CHATTANOOGA, Tenn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Occlusion Perfusion Catheter (OPC), a multi-lumen balloon catheter from Advanced Catheter Therapies (ACT), was recently selected by researchers for use in exploring a new treatment approach for peripheral artery disease (PAD) and restenosis.
  • Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of PAD.
  • To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form.
  • “ Pre-clinical investigation of liquid sirolimus for local drug delivery ” was published September 15, 2023, in Frontiers in Cardiovascular Medicine .